4.9.3Segment

Contract Development & Manufacturing (CDMO)

Contract manufacturers producing API, drug products, biologics, and sterile injectables for pharmaceutical sponsors.

4
Verticals

Overview

Contract Development & Manufacturing (CDMO) covers contract manufacturers producing APIs, drug products, biologics, and sterile injectables for pharmaceutical sponsors. It is a fast-growing outsourcing market — Catalent (acquired by Novo Holdings), Lonza, Thermo Fisher, and Samsung Biologics among the leaders — driven by the outsourcing of complex manufacturing.

Demand is propelled by biologics and sterile-injectable growth, capacity constraints, and supply-chain-resilience concerns (including reshoring). It is capital-intensive and consolidating, with biologics and advanced-modality capacity the highest-value, most sought-after capabilities.

Market snapshot

FragmentationConsolidatingEstimate

Within pharmaceutical manufacturing (NAICS 325412); CDMOs are not separately identified, so the segment is not separately sized by the Census Bureau.

Business model & economics

Revenue model

Development and manufacturing fees on contracted capacity

Key economics

Recurring revenue
High

multi-year manufacturing contracts

EBITDA margin
20–30%
Capex intensity
High

Characteristics

  • Fast-growing outsourcing of complex manufacturing.
  • Biologics and sterile injectables drive demand.
  • Capacity, resilience, and reshoring concerns.

Geographic concentration

AlabamaAlaskaArizonaFloridaGeorgiaIndianaKansasMaineMinnesotaNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasCaliforniaDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeUtahVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandColoradoMassachusettsNew Jersey

CDMO capacity concentrates in the pharma manufacturing belt — New Jersey and Massachusetts — with a growing Colorado bioprocessing cluster.

New JerseyMassachusettsColorado

U.S. Census Bureau — 2022 Statistics of U.S. Businesses (firms by state), NAICS 325412. Concentration shown by location quotient.

M&A deal context

Deal activityHigh

Who’s acquiring

  • CDMO majors & strategics
  • Pharma-services consolidators
  • PE-backed manufacturing platforms

What’s driving deals

  • Acquisition of biologics and advanced-modality capacity.
  • Biologics and sterile-injectable demand.
  • Supply-chain resilience and reshoring.

Verticals in this segment

Find Contract Development & Manufacturing (CDMO) acquisition targets

Search Acquisera’s index for companies classified under Contract Development & Manufacturing (CDMO) (4.9.3) and build a targeted deal pipeline.

Search companies